FIBROTHERAPEUTICS INC

Charleston, SC · Biotech · Private

Modified peptide therapeutics derived from caveolin-1 scaffolding domain for heart failure and fibrotic disease treatment

Grants
$1.8M
7 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Novel Therapeutics for Interstitial Lung Disease: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development$299,930
Federal grantDepartment of Health and Human Services · Phase I · Novel Therapeutics for Interstitial Lung Disease: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development$299,930
Federal grantDepartment of Health and Human Services · Phase I · Development of Modified Caveolin-1 Scaffolding Domain Peptides with Improved Pharmacological Properties as Therapeutic Agents for Scleroderma Skin Disease$259,601
Federal grantDepartment of Health and Human Services · Phase I · Novel Therapeutics for Heart Failure: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development$299,972
Federal grantDepartment of Health and Human Services · Phase I · Novel Therapeutics for Heart Failure: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development$299,972
Federal grantDepartment of Health and Human Services · Phase I · Novel Therapeutics for Heart Failure: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development$6,500
Federal grantDepartment of Health and Human Services · Phase I · Novel Therapeutic for Kidney Failure: A Modified, Water-Soluble Orally-Active Caveolin-1 Scaffolding Domain Peptide with Improved Characteristics for Drug Development$337,740
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3138Nirogyone Therapeutics LLC——
3139SEAK Therapeutics, LLC——
3140ALCAMENA STEM CELL THERAPEUTICS, LLC——
3141FIBROTHERAPEUTICS INC——
3142MARWELL BIO INC.——
3143Iria Pharma, LLC——
3144DINYA DNA INC—$3.8M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.